as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,202.9
Change
+0.9 (0.07%)
Open
₹1,195.0
Prev. Close
₹1,202.0
Day High
₹1,203.0
Day Low
₹1,185.2
Volume Analysis
Traded
713,800
Delivered
496,858
Delivery %
69.61%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (21.2%)
- •Strong operating margin (27.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (37.3%)
- •Strong 3-year revenue growth (16.4%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,226.66 | ₹1,214.83 | ₹1,208.86 | ₹1,197.03 | ₹1,191.06 | ₹1,179.23 | ₹1,173.26 |
| Fibonacci | ₹1,214.83 | ₹1,208.03 | ₹1,203.83 | ₹1,197.03 | ₹1,190.23 | ₹1,186.03 | ₹1,179.23 |
| Camarilla | ₹1,207.8 | ₹1,206.16 | ₹1,204.53 | ₹1,197.03 | ₹1,201.27 | ₹1,199.64 | ₹1,198.01 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+31.46%
1 Week
-0.26%
1 Month
+7.66%
3 Months
+7.4%
6 Months
+15.78%
1 Year
+29.62%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹560.75
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.88%
Net margin 14.16% × asset turnover 0.49x × equity multiplier 2.0x
Company Overview
Sector
Healthcare
Market Cap
₹118,693 Cr
P/E (TTM)
26.2
ROE
21.2%
Book Value
₹279.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Zydus Lifesciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Liquidity (99/100), while Cash Flow (14/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (21.2%); strong operating margin (27.0%). Strong 3-year EPS growth (37.3%).
TopFund Score — Fundamentals Quality
71/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 18.8% CAGR over last 5 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
USFDA inspection at LiqMeds, UK ended with 4 observations on November 13, 2026.
Zydus completed subscription and 50:50 joint venture in Zydus Sunshine on November 11, 2026.
Transcript of the post results earnings call held on November 4, 2026.
Zydus Therapeutics reports Phase 2b saroglitazar data: 39.1% and 32.4% response vs 13.7% placebo.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 | 7,910 |
| Expenses + | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 | 6,015 |
| Operating Profit | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 | 1,894 |
| OPM % | 26.0% | 24.0% | 29.0% | 34.0% | 28.0% | 26.0% | 33.0% | 32.0% | 33.0% | 26.0% | 34.0% | 24.0% | 24.0% |
| Other Income + | 53 | 60 | 160 | 63 | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 126 | 159 |
| Interest | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 | 187 |
| Depreciation | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 530 | 604 |
| Profit before tax | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,369 | 1,262 |
| Tax % | 22.0% | 23.0% | 21.0% | 23.0% | 29.0% | 15.0% | 25.0% | 23.0% | 27.0% | 29.0% | 19.0% | 26.0% | 26.0% |
| Net Profit + | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 1,011 | 928 |
| EPS in Rs | 8 | 8 | 12 | 14 | 9 | 10 | 12 | 15 | 13 | 10 | 13 | 10 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 6 | 6 | 10 | 21 | 20 | 17 | 18 | 6 | 17 | 30 | 16 | 22 | 29 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 | 23,242 | 27,148 | 30,378 |
| Expenses + | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 | 16,183 | 18,673 | 22,183 |
| Operating Profit | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 | 8,195 |
| OPM % | 20.0% | 25.0% | 20.0% | 24.0% | 23.0% | 20.0% | 24.0% | 22.0% | 22.0% | 28.0% | 30.0% | 31.0% | 27.0% |
| Other Income + | 45 | 112 | 127 | 111 | 183 | -264 | -231 | 2,581 | -422 | 293 | 50 | -7 | 48 |
| Interest | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 | 81 | 166 | 439 | 596 |
| Depreciation | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 | 764 | 916 | 1,408 | 2,002 |
| Profit before tax | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 | 6,027 | 6,621 | 5,644 |
| Tax % | 18.0% | 8.0% | 8.0% | 24.0% | 22.0% | 21.0% | 8.0% | 10.0% | 23.0% | 20.0% | 23.0% | 24.0% | — |
| Net Profit + | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,302 |
| EPS in Rs | 11 | 19 | 15 | 17 | 18 | 11 | 21 | 44 | 19 | 38 | 45 | 50 | 42 |
| Dividend Payout % | 21.0% | 17.0% | 22.0% | 20.0% | 19.0% | 30.0% | 17.0% | 6.0% | 31.0% | 8.0% | 24.0% | 2.0% | — |
| Sales growth | 20 | 9 | -1 | 27 | 11 | 8 | 1 | 5 | 14 | 13 | 19 | 17 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,852 | 27,011 | 27,718 |
| Borrowings + | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | 804 | 3,213 | 12,496 | 13,966 |
| Other Liabilities + | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 6,851 | 8,201 | 9,523 | 11,065 | 13,823 |
| Total Liabilities | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 | 55,607 |
| Fixed Assets + | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,188 | 11,521 | 12,368 | 13,134 | 24,106 | 27,698 |
| CWIP | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 | 3,698 | 1,636 |
| Investments | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 6,412 | 7,540 | 8,348 |
| Other Assets + | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 14,451 | 15,328 | 17,925 |
| Total Assets | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 | 55,607 |
| Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 | 100 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | 3,196 | 6,781 | 2,117 |
| Cash from Investing Activity + | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,363 | -7,895 |
| Cash from Financing Activity + | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,779 | 1,995 | 5,807 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 219 | -170 | -75 | 414 | 28 |
| Free Cash Flow | 498 | 936 | -1,623 | -116 | 236 | 2,043 | 2,447 | 1,050 | 1,697 | 2,313 | 5,139 | -530 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 79 | 109 | 81 | 54 | 65 | 116 | 107 | 83 | 85 | 83 | 122 | 44 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 6.99% | 6.66% | 6.81% | 6.85% | 6.85% | 6.69% | 6.74% | 6.81% | 6.86% | 6.86% | 6.83% | 6.66% |
| Promoters | 74.98% | 74.98% | 74.98% | 74.98% | 74.98% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.02% | 75.01% |
| Government | 0.07% | 0.07% | 0.07% | 0.05% | 0.05% | 0.05% | 0.04% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 4.99% | 5.72% | 5.59% | 7.52% | 7.53% | 7.31% | 7.13% | 7.34% | 7.06% | 6.95% | 6.89% | 7.05% |
| DII | 12.96% | 12.55% | 12.56% | 10.59% | 10.61% | 10.95% | 11.09% | 10.86% | 11.08% | 11.2% | 11.27% | 11.28% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Zydus Lifesciences Ltd (this stock) | 118,693 | 26.2 | 4.27 | 21.2% |
| Dr. Reddy S Laboratories | 115,092 | 41.1 | 2.96 | 11.2% |
| Cipla Ltd | 112,563 | 36.2 | 3.18 | 11.6% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Mankind Pharma Limited | 108,424 | 46.5 | 6.16 | 13.1% |
| Aurobindo Pharma Ltd | 104,215 | 25.7 | 2.64 | 10.1% |
Which Mutual Funds Hold Zydus Lifesciences Ltd?
Frequently Asked Questions about Zydus Lifesciences Ltd
Zydus Lifesciences Ltd (ZYDUSLIFE) closed at ₹1,202.9 on NSE on 19 November 2026, up 0.9 (0.07%) from the previous close.
Zydus Lifesciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol ZYDUSLIFE.
Zydus Lifesciences Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 26.2.
Zydus Lifesciences Ltd has a dividend yield of 0.08%.
Zydus Lifesciences Ltd's 52-week high is ₹1,267.0 and its 52-week low is ₹836.0.
Zydus Lifesciences Ltd has a market capitalisation of ₹118,693 crore.
Zydus Lifesciences Ltd has a TopFund Quality Score of 71/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Zydus Lifesciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.